Instinct Bio Secures $150M Equity Funding Facility

Instinct Bio announced it has entered into an indicative term sheet for a proposed equity purchase facility, enabling the company to sell up to US$150 million of its common stock over a three-year period. This facility provides the company with the flexibility to access capital opportunistically, with the purchase price generally based on the volume-weighted average price (VWAP) less a discount. The proceeds are intended to accelerate the development of its regenerative medicine platform, fund working capital, and pursue strategic acquisitions to expand its longevity ecosystem.